Axogen, Inc. (AXGN) Closes BioCircuit Deal; Sees ~$6M Q4'26 and ~$34M 2027 Revenue

Axogen completed its acquisition of BioCircuit, adding FDA-cleared NerveTape. It expects approximately $6M revenue in Q4 2026 and approximately $34M in 2027 from BioCircuit, which was not included in its prior 2026 guidance.Material DetailsContext by AI AnalystThis is a strategic bolt-on with quant…